Answers are grounded in this paper and cite their sources.
Urinary LC-HRMS metabolomics non-invasively reflects cancer-associated biochemical alterations. However, candidate panels are rarely re-tested in new cohorts or checked against confounding factors, and comparative studies between cancers must differentiate shared from disease-specific changes. We applied a sample preparation and LC-HRMS workflow, previously optimized by design of experiments, to a new cohort of 94 participants (29 bladder cancer, BC; 20 prostate cancer, PC; 45 controls). Data processing combined QC-based filtering, grouping of ions into compounds, exclusion of exogenous signals, adjusted models, matched pairs and cross-validation with permutation testing. After quality filtering, 7403 of 14,693 features were retained (median QC RSD 8.6%). Adjusted for age, sex and exogenous signals, 188 compounds differed between BC and controls. Five were tentatively annotated (MSI levels 2–3): glucuronides of 11-oxoetiocholanolone and tetrahydrocortisone (two isomers), Lysophosphatidylcholine (LysoPC(16:0)) and biliverdin, where 11-oxoetiocholanolone glucuronide was the main candidate. Cross-validated classification of BC gave AUC 0.81 in all samples and 0.68 in matched pairs; these internal estimates require independent validation. An apparent BC-PC separation (AUC 0.86) was not significant after adjustment for exogenous signals, and no PC-specific compounds were found. Controlling for exogenous and demographic factors during data processing gives conservative estimates of urinary metabolomic differences and helps to prevent false-positive findings.
No takes yet. Share an insight, caveat, or question.
Frolova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: